These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38304857)

  • 41. Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
    Stinchcombe TE; Jänne PA; Wang X; Bertino EM; Weiss J; Bazhenova L; Gu L; Lau C; Paweletz C; Jaslowski A; Gerstner GJ; Baggstrom MQ; Graziano S; Bearden J; Vokes EE
    JAMA Oncol; 2019 Oct; 5(10):1448-1455. PubMed ID: 31393548
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of
    Zhao C; Jiang T; Li J; Wang Y; Su C; Chen X; Ren S; Li X; Zhou C
    Transl Lung Cancer Res; 2020 Aug; 9(4):1149-1158. PubMed ID: 32953493
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
    Halmos B; Pennell NA; Fu P; Saad S; Gadgeel S; Otterson GA; Mekhail T; Snell M; Kuebler JP; Sharma N; Dowlati A
    Oncologist; 2015 Nov; 20(11):1298-303. PubMed ID: 26306902
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical utility of ramucirumab in non-small-cell lung cancer.
    Uprety D
    Biologics; 2019; 13():133-137. PubMed ID: 31413541
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations.
    Cheunkarndee T; Guo MZ; Houseknecht S; Feliciano JL; Hann CL; Lam VK; Levy BP; Murray JC; Brahmer JR; Forde PM; Marrone KA; Scott SC
    JTO Clin Res Rep; 2024 Jun; 5(6):100686. PubMed ID: 38975613
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
    Kaneda T; Hata A; Tomioka H; Tanaka K; Kaji R; Fujita S; Tomii K; Katakami N
    Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.
    Heredia D; Mas L; Cardona AF; Oyervides V; Motta Guerrero R; Galvez-Nino M; Lara-Mejía L; Aliaga-Macha C; Carracedo C; Varela-Santoyo E; Ramos-Ramírez M; Davila-Dupont D; Martínez J; Cruz-Rico G; Remon J; Arrieta O
    Lung Cancer; 2022 Dec; 174():133-140. PubMed ID: 36379126
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Afatinib as a Potential Therapeutic Option for Patients With NSCLC With
    Wei Y; Jiang B; Liu S; Zhang Z; Fang W; Yang Y; Li X; Zhao J; Zhao H
    JTO Clin Res Rep; 2021 Jul; 2(7):100193. PubMed ID: 34590038
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients.
    Clement MS; Ebert EBF; Meldgaard P; Sorensen BS
    Clin Lung Cancer; 2021 Nov; 22(6):e870-e877. PubMed ID: 34140247
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
    Zhou C; Wu YL; Chen G; Feng J; Liu XQ; Wang C; Zhang S; Wang J; Zhou S; Ren S; Lu S; Zhang L; Hu C; Hu C; Luo Y; Chen L; Ye M; Huang J; Zhi X; Zhang Y; Xiu Q; Ma J; Zhang L; You C
    Lancet Oncol; 2011 Aug; 12(8):735-42. PubMed ID: 21783417
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.
    Kawashima Y; Fukuhara T; Saito H; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Seike M; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M
    Lancet Respir Med; 2022 Jan; 10(1):72-82. PubMed ID: 34454653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
    Cheng Y; He Y; Li W; Zhang HL; Zhou Q; Wang B; Liu C; Walding A; Saggese M; Huang X; Fan M; Wang J; Ramalingam SS
    Target Oncol; 2021 Mar; 16(2):165-176. PubMed ID: 33544337
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
    Wu YL; Lee JS; Thongprasert S; Yu CJ; Zhang L; Ladrera G; Srimuninnimit V; Sriuranpong V; Sandoval-Tan J; Zhu Y; Liao M; Zhou C; Pan H; Lee V; Chen YM; Sun Y; Margono B; Fuerte F; Chang GC; Seetalarom K; Wang J; Cheng A; Syahruddin E; Qian X; Ho J; Kurnianda J; Liu HE; Jin K; Truman M; Bara I; Mok T
    Lancet Oncol; 2013 Jul; 14(8):777-86. PubMed ID: 23782814
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
    Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
    Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials.
    Li R; Li W; Zhang F; Li S
    Eur J Med Res; 2023 Aug; 28(1):302. PubMed ID: 37635242
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.
    Truini A; Starrett JH; Stewart T; Ashtekar K; Walther Z; Wurtz A; Lu D; Park JH; DeVeaux M; Song X; Gettinger S; Zelterman D; Lemmon MA; Goldberg SB; Politi K
    Clin Cancer Res; 2019 Nov; 25(21):6382-6391. PubMed ID: 31182434
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non-small cell lung cancer.
    Huang CY; Huang HL; Lan CC; Huang YC; Wu YK
    BMC Cancer; 2023 May; 23(1):413. PubMed ID: 37158884
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients.
    Scagliotti G; Moro-Sibilot D; Kollmeier J; Favaretto A; Cho EK; Grosch H; Kimmich M; Girard N; Tsai CM; Hsia TC; Brighenti M; Schumann C; Wang XA; Wijayawardana SR; Gruver AM; Wallin J; Mansouri K; Wacheck V; Chang GC
    J Thorac Oncol; 2020 Jan; 15(1):80-90. PubMed ID: 31622732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.